HIGHLIGHTS

453  Selected Articles from This Issue

REVIEW

455  Salting the Soil: Targeting the Microenvironment of Brain Metastases
   Ethan S. Srinivasan, Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw

SMALL MOLECULE THERAPEUTICS

467  Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
   Aaron Balog, Tai-an Lin, Derrick Maley, Johnni Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng, and John T. Hunt

477  A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
   Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xuxia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, and Ethan Dmitrovsky

490  Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
   Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Vaz, Gabriele Cruciani, and Y.N. Vashisht Gopal

500  The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
   Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R. Hodges, Courtney W. Hudgens, Grant M. Fischer, Catherine K. Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. Mackinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng, and Y.N. Vashisht Gopal

LARGE MOLECULE THERAPEUTICS

512  Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX
   Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri, and Samuele Cazzamalli

523  Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
   Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zl, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D. Economides, Douglas E. Williams, and Sriram Sathyarayarayan

   Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, and Richard Gorlick

541  Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
William H. Gmeiner, Anthony Dominijanni, Alex O. Haber, Lais P. Ghiraldeli, David L. Caudell, Ralph D'Agostino Jr, Boris C. Pasche, Thomas L. Smith, Zhiyong Deng, Sezgin Kiren, Chinnaadurai Mani, Komaraiah Palle, and Jonathan R. Brody

Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, and Klaus Elenius

Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells
Yida Zhang, Lile He, Ananthan Sadagopan, Tao Ma, Gianpietro Dotti, Yufeng Wang, Hui Zheng, Xin Gao, Dian Wang, Albert B. DeLeo, Song Fan, Ruochuan Sun, Ling Yu, Liyuan Zhang, Gongsian Wang, Soldano Ferrone, and Xinhuai Wang

Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma
Brandon M. Roane, Selene Meza-Perez, Ashwini A. Katre, Whitney N. Goldsberry, Troy D. Randall, Lyse A. Norian, Michael J. Birrer, and Rebecca C. Arend

The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells
Rupesh Shrestha, Kumaravel Mohankumar, Un-ho Jin, Gregory Martin, and Stephen Safe

Photomicrographic image of a tumor invasive margin from a syngeneic tumor model (MC38) stained with multiplex immunofluorescence to identify macrophages (F4/80⁺; Red) in the tumor microenvironment. Polarization state of these macrophages was determined using inducible nitric oxide synthase (iNOS; Green), a marker for M1 polarization, and arginase I (Arg1; Cyan) a marker for M2 polarization. In the tumor margins, 152-fold increase in M1 macrophages were observed with exoIL-12 treatment. These studies provide evidence that exoIL-12 was significantly more potent than rIL12 and enabled systemic anti-tumor immunity by facilitating prolonged local pharmacology and undetectable systemic exposure. The improved therapeutic index achieved in pre-clinical models support further clinical investigation of this powerful cytokine. Read the full article on p. 523.